Results 151 to 160 of about 38,154 (222)

Effect of PCC on Thrombin Generation among Patients on Factor Xa Inhibitors with Major Bleeding or Needing Urgent Surgery (GAUGE): Design and Rationale. [PDF]

TH Open, 2023
Shaw JR, Unachukwu U, Cyr J, Siegal DM, Castellucci LA, Dreden PV, Dowlatshahi D, Buyukdere H, Ramsay T, Carrier M.   +9 more
europepmc   +1 more source

Aprotinin and its target enzymes in vitro and in vivo [PDF]

, 1990
Birnbaum, B., Fritz, Hans, Hoffmeister, H., Jochum, Marianne   +3 more
core   +1 more source

Effect of the frequently used antiepileptic drugs carbamazepine, gabapentin, and pregabalin on the pharmacokinetics of edoxaban and other oral factor xa inhibitors in healthy volunteers. [PDF]

Front Pharmacol
Lenard A, Hermann SA, Stoll F, Burhenne J, Foerster KI, Czock D, Mikus G, Meid AD, Haefeli WE, Blank A.   +9 more
europepmc   +1 more source

Factor Xa inhibitors versus vitamin K antagonist in morbidly obese patients with venous thromboembolism: a systematic review and meta-analysis. [PDF]

BMC Cardiovasc Disord, 2023
Park DY, An S, Arif AW, Sana MK, Vij A.
europepmc   +1 more source

Andexanet Alfa for Reversal of Factor Xa Inhibitors in Intracranial Hemorrhage: Observational Cohort Study. [PDF]

J Clin Med, 2022
Rauch S, Müller HP, Dreyhaupt J, Ludolph AC, Kassubek J, Althaus K.   +5 more
europepmc   +1 more source

The Efficacy of Andexanet Alfa for the Reversal of Factor Xa Inhibitors Is Not Influenced by Hemodilution with Different Volume Expanders. [PDF]

J Clin Med
Wienhold J, Rossaint R, Vandeput E, Grottke O.   +3 more
europepmc   +1 more source

An Evaluation of Time to Therapeutic Range of Intravenous Unfractionated Heparin After Transitioning From Direct Oral Factor Xa Inhibitors. [PDF]

Hosp Pharm, 2023
Lawing L, Yook J, Ray M, Smith SE.
europepmc   +1 more source

Safety and Efficacy of Oral Direct Factor Xa Inhibitors in Patients With Nephrotic Syndrome: Results From a National Retrospective Study. [PDF]

Kidney Int Rep
Arches C, Jalal-Eddine A, Titeca-Beauport D, Dao M, Lobbedez T, Zaoui P, Masset C, Bertrand D, El Karoui K, Brenier H, Sakhi H, Peiffer B, Audard V, Joher N.   +13 more
europepmc   +1 more source

Incidence and Predictors of Clinical Outcomes in Real-Life Patients With Atrial Fibrillation Treated With Oral Factor Xa Inhibitors: The Follow-Up Results of the ANATOLIA-AF Study. [PDF]

Clin Cardiol
Kocabaş U, Ergin I, Sönmez SC, Yavuz V, Murat S, Özdemir IH, Genç Ö, Tüner H, Meriç BK, Aslan O, Dal A, Taşkın U, Şen T, İbişoğlu E, Erdoğan A, Özgeyik M, Demir M, Urgun ÖD, Doğduş M, Çakal S, Çayırlı S, Güler A, Karabulut D, Dalgıç O, Murat B, Karabulut U, Öztekin GMY, Biter Hİ, Sinan ÜY, Barış VÖ, Kaplan M, Altın C, Kıvrak T.   +32 more
europepmc   +1 more source

Utilization of anti-factor Xa levels to guide reversal of oral factor Xa inhibitors in the emergency department. [PDF]

Am J Health Syst Pharm, 2022
Zepeski AE, Faine BA, Merrill AE, Sutamtewagul G, Bhagavathi S.   +4 more
europepmc   +1 more source